High Response Rate in HCV-Genotype 4 Patients Treated With Ravidasvir and Sofosbuvir
Egypt has the highest prevalence of hepatitis C infection in the world, of which 90% is due to HCV genotype-4 (gt-4). Increasing HCV-related morbidity in Egypt presents an urgent need for highly curative, safe and affordable therapies. We report results from a Phase 3 registrational trial in Egyptian HCV gt-4 patients, assessing the combination of ravidasvir (RDV), a…